Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

NCT04242498 is registered in ClinicalTrials.gov with UCB Biopharma SRL as lead sponsor.

NCT NCT04242498
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04242498 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
Lead sponsor
UCB Biopharma SRL
Phase
Phase 3
Overall status
Completed
Start date
March 2, 2020
Completion date
September 28, 2022
Enrollment
509 (actual)
Sites
91

Conditions

As the registry lists them; a condition with its own page is linked.

hidradenitis suppurativa